FDA approves first pill to prevent recurrent C. difficile infections
The Food and Drug Administration approved the first fecal microbiota product taken orally to prevent recurrent C. difficile infection.
“Today’s approval provides patients and healthcare providers a new way to help prevent recurrent C. difficile infection,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “The availability of a fecal microbiota product that can be taken orally is a significant step forward in advancing patient care and accessibility for individuals who have experienced this disease that can be potentially life-threatening.”
Related News Articles
Headline
The measles outbreak in South Carolina has increased to 876 cases, the state’s Department of Public Health reported Feb. 3. Last week, the South Carolina…
Headline
The Centers for Disease Control and Prevention released its annual progress report on health care-associated infections Jan. 29, which found continued…
Headline
The South Carolina Department of Public Health announced Jan. 30 that the state’s measles outbreak now has 847 cases. The agency said most cases are close…
Headline
(Updated Jan. 23) A measles outbreak in South Carolina has reached 700 cases, the state’s Department of Public Health reported. The outbreak, initially…
Headline
The Centers for Disease Control and Prevention announced Dec. 16 that it adopted individual-based decision-making for parents deciding whether to give the…
Headline
The Centers for Disease Control and Prevention issued an advisory Dec. 3 on an outbreak of Marburg virus in Ethiopia. The agency said a risk of spread to the U…